Procept BioRobotics Reports Major Financial Discrepancies, Shares Plunge
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy PRCT?
Source: PRnewswire
- Financial Discrepancies: Procept BioRobotics reported an adjusted EBITDA loss of $50.2 million for FY 2025, which was $15.2 million or 43% worse than the projected loss of $35 million, leading to a significant drop of over 15% in investor confidence and stock price.
- Revenue Miss: The company generated $308.1 million in revenue for FY 2025, falling short of the guidance of $325.5 million, indicating substantial deficiencies in sales and market performance that could impact future financing and investor trust.
- Earnings Per Share Decline: The Q4 2025 EPS was reported at -$0.53, significantly missing the analyst consensus of -$0.32 by 66%, highlighting severe challenges to the company's profitability and potentially leading to further stock price declines.
- Market Reaction: The management's inability to maintain average selling prices for handpieces at approximately $3,200 and the elimination of historical bulk purchase discounts directly affected realized pricing, raising investor concerns about the company's future profitability.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PRCT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PRCT
Wall Street analysts forecast PRCT stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 24.170
Low
38.00
Averages
51.75
High
65.00
Current: 24.170
Low
38.00
Averages
51.75
High
65.00
About PRCT
PROCEPT BioRobotics Corporation is a commercial-stage surgical robotics company. The Company is focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). The Company's proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH, which are independent of prostate size and shape or surgeon experience.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pomerantz Investigates PROCEPT BioRobotics for Securities Fraud
- Disappointing Financial Results: PROCEPT BioRobotics reported fourth-quarter results on February 25, 2026, revealing revenues that fell significantly short of analyst expectations, prompting a downward revision of its full-year 2026 revenue guidance from $410-$430 million to $390-$410 million, indicating serious operational challenges.
- Significant Stock Decline: Following the earnings report, PROCEPT's stock price plummeted by $4.21, or 15.12%, closing at $23.63 per share on February 26, 2026, reflecting market concerns regarding the company's future outlook.
- Investigation Launched: Pomerantz LLP is investigating whether PROCEPT and its executives engaged in securities fraud or other unlawful business practices, advising investors to contact them for more information, which suggests potential legal risks that could further impact the company.
- Impact of Business Restructuring: The company's mention of a realignment of its commercial organization and the elimination of bulk purchasing discounts for handpieces may lead to customer attrition and a decline in market share, exacerbating its challenges in the competitive medical device market.
See More
Insider Buying Analysis: PROCEPT BioRobotics and Versant Media Group
- Insider Trading at PROCEPT BioRobotics: Antal Rohit Desai purchased 426,262 shares of PRCT at $24.59 each on Monday, totaling $10.48 million, and was up approximately 9.8% at the peak of Tuesday's trading, indicating strong confidence in the company's future performance.
- Price Fluctuation: On Tuesday, PRCT reached a high of $27.00, with PROCEPT BioRobotics trading up about 2.3% on the day, reflecting positive market sentiment regarding its prospects.
- Insider Trading at Versant Media Group: Director David C. Novak bought 143,000 shares at $36.85 each on Thursday, totaling $5.27 million, marking his first purchase in the past twelve months, suggesting optimism about the company's future.
- Market Reaction: Versant Media Group's stock rose about 0.7% on Tuesday, indicating a positive market response to Novak's buying activity, which may enhance investor confidence in the company's outlook.
See More
Procept BioRobotics Reports Discrepancies Leading to Stock Plunge
- Financial Discrepancies: Procept BioRobotics reported an adjusted EBITDA loss of $50.2 million for FY 2025, significantly worse than the management's forecast of $35 million, resulting in a $15.2 million gap that reflects a 43% deviation, undermining investor confidence.
- Revenue Miss: The company generated $308.1 million in revenue for FY 2025, falling short of the guidance of $325.5 million, indicating weak market demand and management's overly optimistic outlook, which could impact future financing capabilities.
- Earnings Per Share Loss: The Q4 2025 EPS was reported at -$0.53, considerably below the analyst consensus of -$0.32, representing a 66% miss that may raise investor concerns regarding the company's profitability, further pressuring the stock price.
- Shareholder Loss Warning: Due to significant discrepancies in financial reporting, Procept's shareholders have seen over a 15% loss in investment value, with legal consultation information provided to assist affected investors in seeking compensation, highlighting potential issues in corporate governance and transparency.
See More
Procept BioRobotics Reports Major Financial Discrepancies, Shares Plunge
- Financial Discrepancies: Procept BioRobotics reported an adjusted EBITDA loss of $50.2 million for FY 2025, which was $15.2 million or 43% worse than the projected loss of $35 million, leading to a significant drop of over 15% in investor confidence and stock price.
- Revenue Miss: The company generated $308.1 million in revenue for FY 2025, falling short of the guidance of $325.5 million, indicating substantial deficiencies in sales and market performance that could impact future financing and investor trust.
- Earnings Per Share Decline: The Q4 2025 EPS was reported at -$0.53, significantly missing the analyst consensus of -$0.32 by 66%, highlighting severe challenges to the company's profitability and potentially leading to further stock price declines.
- Market Reaction: The management's inability to maintain average selling prices for handpieces at approximately $3,200 and the elimination of historical bulk purchase discounts directly affected realized pricing, raising investor concerns about the company's future profitability.
See More
Pomerantz LLP Investigates PROCEPT BioRobotics for Securities Fraud
- Poor Financial Performance: Procept BioRobotics reported fourth-quarter results on February 25, 2026, revealing revenues that significantly missed analyst expectations, prompting a downward revision of its full-year 2026 revenue guidance to $390-$410 million from a previous range of $410-$430 million, indicating substantial market challenges and internal restructuring impacts.
- Significant Stock Decline: Following the earnings report, Procept's stock price plummeted by $4.21, or 15.12%, closing at $23.63 per share on February 26, 2026, reflecting investor concerns about the company's future prospects, which could adversely affect its financing capabilities and market confidence.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Procept and its executives have engaged in securities fraud or other unlawful business practices, which could expose the company to legal liabilities and further exacerbate investor anxiety.
- Impact of Business Restructuring: The company's mention of a realignment of its commercial organization and the elimination of bulk purchasing discounts for handpieces suggests a strategic shift to adapt to market changes, but may negatively affect sales and customer relationships in the short term, increasing uncertainty around future performance.
See More
PROCEPT BioRobotics Outlines 2026 Financial Targets
- 2026 Financial Outlook: PROCEPT expects revenue between $390 million and $410 million in 2026, reflecting a growth rate of 27% to 33%, with a target of 60,000 to 64,000 procedures and a gross margin of 65%, while adjusted EBITDA loss is projected between $30 million and $17 million, with a positive EBITDA expected in Q4, indicating a strong shift towards profitability.
- Market Opportunity and Strategy: CEO Larry Wood highlighted that approximately 400,000 patients undergo prostate procedures annually, with Aquablation penetration at only 10%, indicating a significant untapped market in benign prostatic hyperplasia (BPH) and prostate cancer treatment, which could drive future growth through increased market share.
- Pricing and Sales Strategy Adjustments: PROCEPT has eliminated quarter-end discounting to reduce revenue volatility and enhance average selling prices (ASP), projecting that handpiece ASP will rise to about $3,500 by 2026, a change that is expected to improve margins and support the company's path to profitability.
- Clinical Trial Progress: The ongoing WATER IV trial, involving 280 patients, is on track to present results at the AUA in 2027, and strong data could significantly expand the addressable market, further solidifying the company's strategic positioning in prostate cancer treatment.
See More
Pomerantz Investigates PROCEPT BioRobotics for Securities Fraud
- Disappointing Financial Results: PROCEPT BioRobotics reported fourth-quarter results on February 25, 2026, revealing revenues that fell significantly short of analyst expectations, prompting a downward revision of its full-year 2026 revenue guidance from $410-$430 million to $390-$410 million, indicating serious operational challenges.
- Significant Stock Decline: Following the earnings report, PROCEPT's stock price plummeted by $4.21, or 15.12%, closing at $23.63 per share on February 26, 2026, reflecting market concerns regarding the company's future outlook.
- Investigation Launched: Pomerantz LLP is investigating whether PROCEPT and its executives engaged in securities fraud or other unlawful business practices, advising investors to contact them for more information, which suggests potential legal risks that could further impact the company.
- Impact of Business Restructuring: The company's mention of a realignment of its commercial organization and the elimination of bulk purchasing discounts for handpieces may lead to customer attrition and a decline in market share, exacerbating its challenges in the competitive medical device market.
See More
Insider Buying Analysis: PROCEPT BioRobotics and Versant Media Group
- Insider Trading at PROCEPT BioRobotics: Antal Rohit Desai purchased 426,262 shares of PRCT at $24.59 each on Monday, totaling $10.48 million, and was up approximately 9.8% at the peak of Tuesday's trading, indicating strong confidence in the company's future performance.
- Price Fluctuation: On Tuesday, PRCT reached a high of $27.00, with PROCEPT BioRobotics trading up about 2.3% on the day, reflecting positive market sentiment regarding its prospects.
- Insider Trading at Versant Media Group: Director David C. Novak bought 143,000 shares at $36.85 each on Thursday, totaling $5.27 million, marking his first purchase in the past twelve months, suggesting optimism about the company's future.
- Market Reaction: Versant Media Group's stock rose about 0.7% on Tuesday, indicating a positive market response to Novak's buying activity, which may enhance investor confidence in the company's outlook.
See More
Procept BioRobotics Reports Discrepancies Leading to Stock Plunge
- Financial Discrepancies: Procept BioRobotics reported an adjusted EBITDA loss of $50.2 million for FY 2025, significantly worse than the management's forecast of $35 million, resulting in a $15.2 million gap that reflects a 43% deviation, undermining investor confidence.
- Revenue Miss: The company generated $308.1 million in revenue for FY 2025, falling short of the guidance of $325.5 million, indicating weak market demand and management's overly optimistic outlook, which could impact future financing capabilities.
- Earnings Per Share Loss: The Q4 2025 EPS was reported at -$0.53, considerably below the analyst consensus of -$0.32, representing a 66% miss that may raise investor concerns regarding the company's profitability, further pressuring the stock price.
- Shareholder Loss Warning: Due to significant discrepancies in financial reporting, Procept's shareholders have seen over a 15% loss in investment value, with legal consultation information provided to assist affected investors in seeking compensation, highlighting potential issues in corporate governance and transparency.
See More
Procept BioRobotics Reports Major Financial Discrepancies, Shares Plunge
- Financial Discrepancies: Procept BioRobotics reported an adjusted EBITDA loss of $50.2 million for FY 2025, which was $15.2 million or 43% worse than the projected loss of $35 million, leading to a significant drop of over 15% in investor confidence and stock price.
- Revenue Miss: The company generated $308.1 million in revenue for FY 2025, falling short of the guidance of $325.5 million, indicating substantial deficiencies in sales and market performance that could impact future financing and investor trust.
- Earnings Per Share Decline: The Q4 2025 EPS was reported at -$0.53, significantly missing the analyst consensus of -$0.32 by 66%, highlighting severe challenges to the company's profitability and potentially leading to further stock price declines.
- Market Reaction: The management's inability to maintain average selling prices for handpieces at approximately $3,200 and the elimination of historical bulk purchase discounts directly affected realized pricing, raising investor concerns about the company's future profitability.
See More
Pomerantz LLP Investigates PROCEPT BioRobotics for Securities Fraud
- Poor Financial Performance: Procept BioRobotics reported fourth-quarter results on February 25, 2026, revealing revenues that significantly missed analyst expectations, prompting a downward revision of its full-year 2026 revenue guidance to $390-$410 million from a previous range of $410-$430 million, indicating substantial market challenges and internal restructuring impacts.
- Significant Stock Decline: Following the earnings report, Procept's stock price plummeted by $4.21, or 15.12%, closing at $23.63 per share on February 26, 2026, reflecting investor concerns about the company's future prospects, which could adversely affect its financing capabilities and market confidence.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Procept and its executives have engaged in securities fraud or other unlawful business practices, which could expose the company to legal liabilities and further exacerbate investor anxiety.
- Impact of Business Restructuring: The company's mention of a realignment of its commercial organization and the elimination of bulk purchasing discounts for handpieces suggests a strategic shift to adapt to market changes, but may negatively affect sales and customer relationships in the short term, increasing uncertainty around future performance.
See More
PROCEPT BioRobotics Outlines 2026 Financial Targets
- 2026 Financial Outlook: PROCEPT expects revenue between $390 million and $410 million in 2026, reflecting a growth rate of 27% to 33%, with a target of 60,000 to 64,000 procedures and a gross margin of 65%, while adjusted EBITDA loss is projected between $30 million and $17 million, with a positive EBITDA expected in Q4, indicating a strong shift towards profitability.
- Market Opportunity and Strategy: CEO Larry Wood highlighted that approximately 400,000 patients undergo prostate procedures annually, with Aquablation penetration at only 10%, indicating a significant untapped market in benign prostatic hyperplasia (BPH) and prostate cancer treatment, which could drive future growth through increased market share.
- Pricing and Sales Strategy Adjustments: PROCEPT has eliminated quarter-end discounting to reduce revenue volatility and enhance average selling prices (ASP), projecting that handpiece ASP will rise to about $3,500 by 2026, a change that is expected to improve margins and support the company's path to profitability.
- Clinical Trial Progress: The ongoing WATER IV trial, involving 280 patients, is on track to present results at the AUA in 2027, and strong data could significantly expand the addressable market, further solidifying the company's strategic positioning in prostate cancer treatment.
See More
